In its communication, Cipla stated that Pharmathen International S.A., based in Greece, manufactures and exclusively supplies ...

Regulatory action at Pharmathen’s main manufacturing site in Greece could potentially disrupt supplies of one of Cipla’s ...

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...

Cipla had earlier received final USFDA approval in May 2024 to market its generic Lanreotide injection in multiple strengths.

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

Cipla clarified that its supply partner Pharmathen received nine USFDA Form 483 observations during a November 2025 ...

MISSISSAUGA, ON, Jan. 7, 2020 /CNW/ - Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline ® Autogel ® (lanreotide injection) 60, 90, and 120 ...

Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores. Findings from a recently ...

Afinitor plus Somatuline significantly improved PFS in GEP-NETs compared to Afinitor monotherapy, with median PFS of 29.7 vs. 11.5 months. The combination therapy showed a higher objective response ...